Management of infections for patient treated with ibrutinib in clinical practice

Ibrutinib, a highly effective inhibitor of the Bruton tyrosine kinase, has significantly transformed the therapeutic approach in chronic lymphocytic leukemia (CLL). Despite these advancements, the disease continues to be characterized by immune dysfunction and increased susceptibility to infections,...

Полное описание

Библиографические подробности

Главные авторы:	Claudia Baratè, Ilaria Scortechini, Sara Ciofini, Paola Picardi, Ilaria Angeletti, Federica Loscocco, Alessandro Sanna, Alessandro Isidori, Paolo Sportoletti
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2024-09-01
Серии:	Frontiers in Oncology
Предметы:	CLL ibrutinib infection recommendation prophylaxis
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1428464/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!